Fc Fusion Therapeutics Market, 2021-2030 Distribution by Target Indications (Neutropenia, Graft Versus Host Disease, Breast Cancer, Rheumatoid Arthritis, Non-Small Cell Lung Cancer, Neovascular (Wet) Age-related Macular Degeneration (AMD), Hemophilia A, N
Description
Fc Fusion Therapeutics Market, 2021-2030 Distribution by Target Indications (Neutropenia, Graft Versus Host Disease, Breast Cancer, Rheumatoid Arthritis, Non-Small Cell Lung Cancer, Neovascular (Wet) Age-related Macular Degeneration (AMD), Hemophilia A, Neuromyelitis Optica Spectrum Disorders and Systemic Lupus Erythematosus), Type of Fusion Molecule (Antibody, Cytokine, Growth Factor, Receptor ECD and Others), Route of Administration (Subcutaneous, Intravenous and Intravitreal) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030
Since the approval of Enbrel®, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including Arcalyst® (recurrent pericarditis, March 2021), Reblozyl® (beta-thalassemia, September 2020) and Alprolix® (haemophilia B, May 2016) were approved recently. These molecules combine the beneficial pharmacological properties of biologically active ligands with the properties of the crystallizable fragment (Fc) domain of an immunoglobulin G (IgG). It is worth highlighting that these advanced variants of immunoglobulin derived therapeutic candidates are protected from lysosomal degradation once they are taken up by endothelial cells and later released back into the bloodstream by binding of the Fc-fragment to FcRn receptors present in endosomes. This prolongs the exposure of the pharmacologically active moieties to the target tissue thereby, increasing their therapeutic efficacy. Given their ability to extend the serum half-life of biologically active proteins, these disease-modifying interventions find applications across different therapeutic areas (including but not limited to oncological disorders, neurological disorders, respiratory disorders, rare genetic disorders).
Presently, several drug developers are actively engaged in the development of novel Fc fusion therapies with enhanced efficacy. The research in this field is focused on improving the stability and solubility of pharmacologically active moiety, thereby, improving its therapeutic potential. Further, several big pharma players have demonstrated interest in Fc fusion therapeutics and are investing both time and capital in this domain. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Moreover, the market has witnessed substantial partnership activity over the last few years. Given the ongoing efforts and the encouraging clinical trial results, the Fc fusion therapies market is poised to witness healthy growth as more drug candidates get approved and marketed over the coming decade.
SCOPE OF THE REPORT
The “Fc Fusion Therapeutics Market by Target Indications (Neutropenia, Graft Versus Host Disease, Breast Cancer, Rheumatoid Arthritis, Non-Small Cell Lung Cancer, Neovascular (Wet) Age-related Macular Degeneration (AMD), Hemophilia A, Neuromyelitis Optica Spectrum Disorders and Systemic Lupus Erythematosus) Type of Fusion Molecule (Antibody, Cytokine, Growth Factor, Receptor ECD and Others) Route of Administration (Subcutaneous, Intravenous and Intravitreal) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies till 2030. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
A detailed assessment of the current market landscape of Fc fusion therapeutics, providing information on phase of development (marketed, clinical and pre-clinical) of lead candidates, type of fusion molecule (antibody based, cytokine based, enzyme based, growth factor based, peptide based, receptor ECD based and others), target gene, therapeutic area(s), target disease indication(s), type of therapy (combination therapy and monotherapy), route of administration (intravenous, intravitreal, oral and subcutaneous) and dosing frequency. In addition, the chapter includes information on the drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
Elaborate profiles of key players involved in the development of Fc fusion therapeutics. Each profile features a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
An in-depth analysis of completed, ongoing and planned clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as trial registration year, trial phase, study design, type of masking, type of intervention model, emerging focus area, leading industry sponsors / collaborators (in terms of number of trials conducted), popular indications, popular interventions and regional distribution of trials.
A study of the various grants that have been awarded to research institutes engaged in conducting projects related to Fc fusion therapeutics, between 2010 and 2021 (till May), including analyses based on several relevant parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code and emerging focus areas. In addition, it highlights the popular NIH departments, prominent program officers, and popular recipient organizations (in terms of number of grants awarded).
A detailed review of close to 1,135 peer-reviewed, scientific articles related to Fc fusion therapeutics, which have been published between 2010 and 2021 (till August). It discusses the trends across parameters, such as year of publication, emerging focus areas, target therapeutic area, leading authors, and key journals (in terms of number of articles published in this domain).
An in-depth analysis of the patents that have been filed / granted related to Fc fusion therapeutics, since 2018. It includes information on various parameters, such as patent publication year, type of patent, geographical location / patent jurisdiction, patent age, CPC symbols, emerging focus areas, and the leading / academic players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.
An analysis of the partnerships established between various stakeholders in this domain, during the period 2016-2021 (till August), covering product development and commercialization, R&D agreements, mergers / acquisitions, clinical trial agreements, and other relevant types of deals.
A case study on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as phase of development, target disease indication, therapeutic area, type of Fc engineering, impact of Fc engineering, route of administration, and type of therapy. It also highlights the players involved in the development of these Fc protein and glycoengineered antibodies.
One of the key objectives of the report was to estimate the existing market size and the future growth opportunities for Fc fusion therapeutics, over the next few years. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target indications (neutropenia, graft versus host disease, breast cancer, rheumatoid arthritis, non-small cell lung cancer, neovascular (wet) age-related macular degeneration (AMD), hemophilia A, neuromyelitis optica spectrum disorders and Systemic lupus erythematosus) [B] type of fusion molecule (antibody, cytokine, growth factor, receptor ECD and others) [C] route of administration (subcutaneous, intravenous and intravitreal) and [D] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in the report are in USD, unless otherwise specified.
KEY QUESTIONS ANSWERED
Who are the leading industry players involved in the development of Fc fusion therapeutics?
Which geographies are the most active in conducting clinical trials on Fc fusion therapeutics?
Which are the leading funding organizations providing grants for Fc fusion therapeutics?
Which partnership models are commonly adopted by industry stakeholders in the development of Fc fusion therapeutics?
How is the current and future market opportunity likely to be distributed across key market segments?
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the Fc fusion therapeutics market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to Fc fusion therapeutics, components of Fc fusion along with their mechanism of action and types. Additionally, it also highlights the applications of Fc fusion therapeutics, laying emphasis on the emerging trends and how this field of research is likely to evolve over the coming decade.
Chapter 4 includes information on over 110 programs for Fc fusion therapeutics that are either approved or being developed across different stages (commercial, clinical, and preclinical) for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and pre-clinical) of lead candidates, type of fusion molecule (antibody based, cytokine based, enzyme based, growth factor based, peptide based, Receptor ECD based and others), target gene, therapeutic area(s), target disease indication(s), type of therapy (combination therapy and monotherapy), route of administration (intravenous, intravitreal, oral and subcutaneous) and dosing frequency. In addition, the chapter includes information on drug developer(s), highlighting their year of their establishment, company size, and location of headquarters.
Chapter 5 provides detailed profiles of the stakeholders involved in the development of Fc fusion therapeutics. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, and recent developments and an informed future outlook.
Chapter 6 provides a detailed analysis of completed, ongoing and planned clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as trial registration year, trial phase, study design, type of masking, type of intervention model, emerging focus area, leading industry sponsors / collaborators (in terms of number of trials conducted), popular indications, popular interventions and regional distribution of trials.
Chapter 7 provides an analysis of more than 200 grants that have been awarded to research institutes engaged in projects related to Fc fusion therapeutics, between 2010 and 2021 (till May), on the basis of important parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code and emerging focus areas. In addition, it highlights the popular NIH departments, prominent program officers, and popular recipient organizations (in terms of number of grants awarded).
Chapter 8 provides a detailed analysis of over 1,100 research articles related to Fc fusion therapeutics, published between 2010 and 2021 (till August). The analysis takes into consideration several parameters, such as year of publication, emerging focus areas, target therapeutic area, leading authors, and key journals (in terms of number of articles published in this domain).
Chapter 9 provides an overview of the various patents that have been filed / granted related to Fc fusion therapeutics, since 2018. It includes information on various parameters, such as patent publication year, type of patent, geographical location / patent jurisdiction, patent age, CPC symbols, emerging focus areas, and the leading / academic players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 10 features an analysis of the various collaborations and partnerships that have been established amongst various stakeholders in this domain. It includes information on various parameters, such as year of partnerships, type of partnerships, leading players (in terms of collaborations inked) and regional distribution. We have discussed different partnership models (including product development and commercialization, R&D agreements, mergers / acquisitions and clinical trial agreements) that have been established till 2021 (till August).
Chapter 11 features a detailed market forecast analysis, highlighting the likely growth of Fc fusion therapeutics till the year 2030. We have provided inputs on the likely distribution of the market opportunity based on different target indications (neutropenia, graft versus host disease, breast cancer, rheumatoid arthritis, non-small cell lung cancer, neovascular (wet) age-related macular degeneration (AMD), hemophilia A, neuromyelitis optica spectrum disorders and systemic lupus erythematosus), type of fusion molecule (antibody, cytokine, growth factor, receptor ECD and others), route of administration (subcutaneous, intravenous and intravitreal) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 12 features a case study on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as phase of development, target disease indication, therapeutic area, type of Fc engineering, impact of Fc engineering, route of administration, and type of therapy. It also provides details on the players involved in the development of these Fc protein and glycoengineered antibodies
Chapter 13 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the Fc fusion therapeutics market.
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
1. 3SBio
2. AbbVie
3. Acceleron Pharma
4. AdAlta
5. Agenus
6. Akeso
7. Alexion Pharmaceuticals
8. Alphamab Oncology
9. Amgen
10. Anthera Pharmaceuticals
11. Apogenix
12. argenx
13. AstraZeneca
14. Bayer
15. BeiGene
16. BIOCAD
17. Biogen
18. Boehringer Ingelheim
19. Brigham and Women's Hospital (BWH)
20. Bristol Myers Squibb
21. CANbridge Pharmaceuticals
22. Cantargia
23. Celgene
24. Celldex Therapeutics
25. Chengdu Kanghong Pharmaceutical
26. Chia Tai Tianqing Pharmaceutical
27. Chiesi Farmaceutici
28. CSL Behring
29. Daiichi Sankyo
30. Dana-Farber Cancer Institute
31. Eli Lilly
32. Evive Biotech
33. Forbius
34. Genentech
35. Gilead Sciences
36. GlaxoSmithKline
37. Haimen Gensciences
38. Harvard College
39. Horizon Therapeutics
40. Huabo Biopharm
41. Humanigen
42. Incyte
43. Inhibrx
44. National Institute of Health and Medical Research (Inserm)
45. Jiangsu Gensciences
46. Johnson & Johnson
47. Junshi Biosciences
48. KBI Biopharma
49. Kiniksa Pharmaceuticals
50. Kyowa Kirin
51. LEO Pharma
52. MacroGenics
53. Memorial Sloan Kettering Cancer Center
54. Menarini
55. Merck
56. MorphoSys
57. National Cancer Institute (NCI)
58. National Institute of Allergy and Infectious Diseases (NIAID)
59. NGM Biopharmaceuticals
60. Novartis
61. OncoImmune (acquired by Merck)
62. Pfizer
63. Protalix Biotherapeutics
64. Provention Bio
65. Regeneron Pharmaceuticals
66. RemeGen
67. Resolve Therapeutics
68. Roche
69. Sanofi
70. Seagen
71. Shandong TheraWisdom Biopharma
72. Shanghai Henlius Biotech
73. Swedish Orphan Biovitrum (Sobi)
74. SYNIMMUNE
75. SystImmune
76. Takeda Pharmaceutical
77. TG Therapeutics
78. Tiziana Life Sciences
79. United BioPharma (UBP)
80. United States Department of Health and Human Services (HHS)
81. University of California
82. University of Pennsylvania
83. USHEALTH
84. Vir Biotechnology
85. Visterra
86. Xencor
87. Zhejiang Hisun Pharmaceutical
88. Zhengzhou Gensciences
89. Zymeworks
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Since the approval of Enbrel®, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including Arcalyst® (recurrent pericarditis, March 2021), Reblozyl® (beta-thalassemia, September 2020) and Alprolix® (haemophilia B, May 2016) were approved recently. These molecules combine the beneficial pharmacological properties of biologically active ligands with the properties of the crystallizable fragment (Fc) domain of an immunoglobulin G (IgG). It is worth highlighting that these advanced variants of immunoglobulin derived therapeutic candidates are protected from lysosomal degradation once they are taken up by endothelial cells and later released back into the bloodstream by binding of the Fc-fragment to FcRn receptors present in endosomes. This prolongs the exposure of the pharmacologically active moieties to the target tissue thereby, increasing their therapeutic efficacy. Given their ability to extend the serum half-life of biologically active proteins, these disease-modifying interventions find applications across different therapeutic areas (including but not limited to oncological disorders, neurological disorders, respiratory disorders, rare genetic disorders).
Presently, several drug developers are actively engaged in the development of novel Fc fusion therapies with enhanced efficacy. The research in this field is focused on improving the stability and solubility of pharmacologically active moiety, thereby, improving its therapeutic potential. Further, several big pharma players have demonstrated interest in Fc fusion therapeutics and are investing both time and capital in this domain. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Moreover, the market has witnessed substantial partnership activity over the last few years. Given the ongoing efforts and the encouraging clinical trial results, the Fc fusion therapies market is poised to witness healthy growth as more drug candidates get approved and marketed over the coming decade.
SCOPE OF THE REPORT
The “Fc Fusion Therapeutics Market by Target Indications (Neutropenia, Graft Versus Host Disease, Breast Cancer, Rheumatoid Arthritis, Non-Small Cell Lung Cancer, Neovascular (Wet) Age-related Macular Degeneration (AMD), Hemophilia A, Neuromyelitis Optica Spectrum Disorders and Systemic Lupus Erythematosus) Type of Fusion Molecule (Antibody, Cytokine, Growth Factor, Receptor ECD and Others) Route of Administration (Subcutaneous, Intravenous and Intravitreal) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies till 2030. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
A detailed assessment of the current market landscape of Fc fusion therapeutics, providing information on phase of development (marketed, clinical and pre-clinical) of lead candidates, type of fusion molecule (antibody based, cytokine based, enzyme based, growth factor based, peptide based, receptor ECD based and others), target gene, therapeutic area(s), target disease indication(s), type of therapy (combination therapy and monotherapy), route of administration (intravenous, intravitreal, oral and subcutaneous) and dosing frequency. In addition, the chapter includes information on the drug developer(s), highlighting their year of establishment, company size, and location of headquarters.
Elaborate profiles of key players involved in the development of Fc fusion therapeutics. Each profile features a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
An in-depth analysis of completed, ongoing and planned clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as trial registration year, trial phase, study design, type of masking, type of intervention model, emerging focus area, leading industry sponsors / collaborators (in terms of number of trials conducted), popular indications, popular interventions and regional distribution of trials.
A study of the various grants that have been awarded to research institutes engaged in conducting projects related to Fc fusion therapeutics, between 2010 and 2021 (till May), including analyses based on several relevant parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code and emerging focus areas. In addition, it highlights the popular NIH departments, prominent program officers, and popular recipient organizations (in terms of number of grants awarded).
A detailed review of close to 1,135 peer-reviewed, scientific articles related to Fc fusion therapeutics, which have been published between 2010 and 2021 (till August). It discusses the trends across parameters, such as year of publication, emerging focus areas, target therapeutic area, leading authors, and key journals (in terms of number of articles published in this domain).
An in-depth analysis of the patents that have been filed / granted related to Fc fusion therapeutics, since 2018. It includes information on various parameters, such as patent publication year, type of patent, geographical location / patent jurisdiction, patent age, CPC symbols, emerging focus areas, and the leading / academic players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.
An analysis of the partnerships established between various stakeholders in this domain, during the period 2016-2021 (till August), covering product development and commercialization, R&D agreements, mergers / acquisitions, clinical trial agreements, and other relevant types of deals.
A case study on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as phase of development, target disease indication, therapeutic area, type of Fc engineering, impact of Fc engineering, route of administration, and type of therapy. It also highlights the players involved in the development of these Fc protein and glycoengineered antibodies.
One of the key objectives of the report was to estimate the existing market size and the future growth opportunities for Fc fusion therapeutics, over the next few years. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target indications (neutropenia, graft versus host disease, breast cancer, rheumatoid arthritis, non-small cell lung cancer, neovascular (wet) age-related macular degeneration (AMD), hemophilia A, neuromyelitis optica spectrum disorders and Systemic lupus erythematosus) [B] type of fusion molecule (antibody, cytokine, growth factor, receptor ECD and others) [C] route of administration (subcutaneous, intravenous and intravitreal) and [D] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in the report are in USD, unless otherwise specified.
KEY QUESTIONS ANSWERED
Who are the leading industry players involved in the development of Fc fusion therapeutics?
Which geographies are the most active in conducting clinical trials on Fc fusion therapeutics?
Which are the leading funding organizations providing grants for Fc fusion therapeutics?
Which partnership models are commonly adopted by industry stakeholders in the development of Fc fusion therapeutics?
How is the current and future market opportunity likely to be distributed across key market segments?
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the Fc fusion therapeutics market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general introduction to Fc fusion therapeutics, components of Fc fusion along with their mechanism of action and types. Additionally, it also highlights the applications of Fc fusion therapeutics, laying emphasis on the emerging trends and how this field of research is likely to evolve over the coming decade.
Chapter 4 includes information on over 110 programs for Fc fusion therapeutics that are either approved or being developed across different stages (commercial, clinical, and preclinical) for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and pre-clinical) of lead candidates, type of fusion molecule (antibody based, cytokine based, enzyme based, growth factor based, peptide based, Receptor ECD based and others), target gene, therapeutic area(s), target disease indication(s), type of therapy (combination therapy and monotherapy), route of administration (intravenous, intravitreal, oral and subcutaneous) and dosing frequency. In addition, the chapter includes information on drug developer(s), highlighting their year of their establishment, company size, and location of headquarters.
Chapter 5 provides detailed profiles of the stakeholders involved in the development of Fc fusion therapeutics. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, and recent developments and an informed future outlook.
Chapter 6 provides a detailed analysis of completed, ongoing and planned clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as trial registration year, trial phase, study design, type of masking, type of intervention model, emerging focus area, leading industry sponsors / collaborators (in terms of number of trials conducted), popular indications, popular interventions and regional distribution of trials.
Chapter 7 provides an analysis of more than 200 grants that have been awarded to research institutes engaged in projects related to Fc fusion therapeutics, between 2010 and 2021 (till May), on the basis of important parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code and emerging focus areas. In addition, it highlights the popular NIH departments, prominent program officers, and popular recipient organizations (in terms of number of grants awarded).
Chapter 8 provides a detailed analysis of over 1,100 research articles related to Fc fusion therapeutics, published between 2010 and 2021 (till August). The analysis takes into consideration several parameters, such as year of publication, emerging focus areas, target therapeutic area, leading authors, and key journals (in terms of number of articles published in this domain).
Chapter 9 provides an overview of the various patents that have been filed / granted related to Fc fusion therapeutics, since 2018. It includes information on various parameters, such as patent publication year, type of patent, geographical location / patent jurisdiction, patent age, CPC symbols, emerging focus areas, and the leading / academic players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 10 features an analysis of the various collaborations and partnerships that have been established amongst various stakeholders in this domain. It includes information on various parameters, such as year of partnerships, type of partnerships, leading players (in terms of collaborations inked) and regional distribution. We have discussed different partnership models (including product development and commercialization, R&D agreements, mergers / acquisitions and clinical trial agreements) that have been established till 2021 (till August).
Chapter 11 features a detailed market forecast analysis, highlighting the likely growth of Fc fusion therapeutics till the year 2030. We have provided inputs on the likely distribution of the market opportunity based on different target indications (neutropenia, graft versus host disease, breast cancer, rheumatoid arthritis, non-small cell lung cancer, neovascular (wet) age-related macular degeneration (AMD), hemophilia A, neuromyelitis optica spectrum disorders and systemic lupus erythematosus), type of fusion molecule (antibody, cytokine, growth factor, receptor ECD and others), route of administration (subcutaneous, intravenous and intravitreal) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 12 features a case study on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as phase of development, target disease indication, therapeutic area, type of Fc engineering, impact of Fc engineering, route of administration, and type of therapy. It also provides details on the players involved in the development of these Fc protein and glycoengineered antibodies
Chapter 13 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the Fc fusion therapeutics market.
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.
LIST OF COMPANIES AND ORGANIZATIONS
1. 3SBio
2. AbbVie
3. Acceleron Pharma
4. AdAlta
5. Agenus
6. Akeso
7. Alexion Pharmaceuticals
8. Alphamab Oncology
9. Amgen
10. Anthera Pharmaceuticals
11. Apogenix
12. argenx
13. AstraZeneca
14. Bayer
15. BeiGene
16. BIOCAD
17. Biogen
18. Boehringer Ingelheim
19. Brigham and Women's Hospital (BWH)
20. Bristol Myers Squibb
21. CANbridge Pharmaceuticals
22. Cantargia
23. Celgene
24. Celldex Therapeutics
25. Chengdu Kanghong Pharmaceutical
26. Chia Tai Tianqing Pharmaceutical
27. Chiesi Farmaceutici
28. CSL Behring
29. Daiichi Sankyo
30. Dana-Farber Cancer Institute
31. Eli Lilly
32. Evive Biotech
33. Forbius
34. Genentech
35. Gilead Sciences
36. GlaxoSmithKline
37. Haimen Gensciences
38. Harvard College
39. Horizon Therapeutics
40. Huabo Biopharm
41. Humanigen
42. Incyte
43. Inhibrx
44. National Institute of Health and Medical Research (Inserm)
45. Jiangsu Gensciences
46. Johnson & Johnson
47. Junshi Biosciences
48. KBI Biopharma
49. Kiniksa Pharmaceuticals
50. Kyowa Kirin
51. LEO Pharma
52. MacroGenics
53. Memorial Sloan Kettering Cancer Center
54. Menarini
55. Merck
56. MorphoSys
57. National Cancer Institute (NCI)
58. National Institute of Allergy and Infectious Diseases (NIAID)
59. NGM Biopharmaceuticals
60. Novartis
61. OncoImmune (acquired by Merck)
62. Pfizer
63. Protalix Biotherapeutics
64. Provention Bio
65. Regeneron Pharmaceuticals
66. RemeGen
67. Resolve Therapeutics
68. Roche
69. Sanofi
70. Seagen
71. Shandong TheraWisdom Biopharma
72. Shanghai Henlius Biotech
73. Swedish Orphan Biovitrum (Sobi)
74. SYNIMMUNE
75. SystImmune
76. Takeda Pharmaceutical
77. TG Therapeutics
78. Tiziana Life Sciences
79. United BioPharma (UBP)
80. United States Department of Health and Human Services (HHS)
81. University of California
82. University of Pennsylvania
83. USHEALTH
84. Vir Biotechnology
85. Visterra
86. Xencor
87. Zhejiang Hisun Pharmaceutical
88. Zhengzhou Gensciences
89. Zymeworks
Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.
Table of Contents
150 Pages
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 3. INTRODUCTION
- 3.1. Overview of Fc Fusion Therapeutics
- 3.2. Components of Fc Fusion Therapeutics
- 3.3. Mechanism of Action
- 3.4. Types of Fc Fusion Therapeutics
- 3.4.1. Antibody-based Fc Fusion Therapeutics
- 3.4.2. Cytokine-based Fc Fusion Therapeutics
- 3.4.3. Enzyme-based Fc Fusion Therapeutics
- 3.4.4. Peptide-based Fc Fusion Therapeutics
- 3.4.5. Receptor ECD-based Fc Fusion Therapeutics
- 3.5. Applications of Fc Fusion Therapeutics
- 3.6. Advantages of Fc Fusion Therapeutics over Other Biological Moieties
- 3.7. Future Perspectives
- 4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS
- 4.1. Analysis Methodology and Key Parameters
- 4.2. Fc Fusion Therapeutics: Drug Pipeline
- 4.3. Fc Fusion Therapeutics: Pipeline Analysis
- 4.3.1. Analysis by Phase of Development
- 4.3.2. Analysis by Type of Fusion Molecule
- 4.3.3. Analysis by Target Gene
- 4.3.4. Analysis by Therapeutic Area(s)
- 4.3.5. Analysis by Target Disease Indication(s)
- 4.3.6. Analysis by Type of Therapy
- 4.3.7. Analysis by Route of Administration
- 4.3.8. Analysis by Dosing Frequency
- 4.4. Fc Fusion Therapeutics: List of Drug Developers
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Company Size
- 4.4.3. Analysis by Location of Headquarters
- 4.4.4. Leading Developers
- 4.4.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
- 5. COMPANY PROFILES
- 5.1. Chapter Overview
- 5.2. Alphamab Oncology
- 5.2.1. Company Overview
- 5.2.2. Financial Information
- 5.2.3. Product Portfolio
- 5.2.4. Recent Developments and Future Outlook
- 5.3. Amgen
- 5.3.1. Company Overview
- 5.3.2. Financial Information
- 5.3.3. Product Portfolio
- 5.3.4. Recent Developments and Future Outlook
- 5.4. Acceleron Pharmaceuticals
- 5.4.1. Company Overview
- 5.4.2. Financial Information
- 5.4.3. Product Portfolio
- 5.4.4. Recent Developments and Future Outlook
- 5.5. Bristol Myers Squibb
- 5.5.1. Company Overview
- 5.5.2. Financial Information
- 5.5.3. Product Portfolio
- 5.5.4. Recent Developments and Future Outlook
- 5.6. Sanofi
- 5.6.1. Company Overview
- 5.6.2. Financial Information
- 5.6.3. Product Portfolio
- 5.6.4. Recent Developments and Future Outlook
- 6. CLINICAL TRIAL ANALYSIS
- 6.1. Analysis Methodology and Key Parameters
- 6.2. Fc Fusion Therapeutics: List of Clinical Trials
- 6.3.1. Analysis by Trial Registration Year
- 6.3.4. Analysis by Trial Phase
- 6.3.3. Analysis by Study Design
- 6.3.2. Analysis by Type of Masking
- 6.3.3. Analysis by Type of Intervention Model
- 6.3.9. World Cloud: Emerging Focus Areas
- 6.3.8. Analysis by Trial Registration Year and Geography
- 6.3.5. Analysis by Type of Sponsor
- 6.3.6. Leading Industry Players: Analysis by Number of Trials Registered
- 6.3.7. Leading Non-Industry Players: Analysis by Number of Trials Registered
- 6.3.10. Popular Indications: Analysis by Number of Registered Trials
- 6.3.11. Popular Interventions: Analysis by Number of Registered Trials
- 6.3.12. Geographical Analysis by Number of Registered Trials
- 6.3.13. Geographical Analysis by Number of Patients Enrolled
- 7. ACADEMIC GRANT ANALYSIS
- 7.1. Analysis Methodology and Key Parameters
- 7.2. Fc Fusion Therapeutics: Analysis of Academic Grants
- 7.2.1. Analysis by Year of Grant Award
- 7.2.2. Analysis by Amount Awarded
- 7.2.3. Analysis by Administering Institute Center
- 7.2.4. Analysis by Support Period
- 7.2.5. Analysis by Type of Grant Application
- 7.2.6. Analysis by Purpose of Grant Award
- 7.2.7. Analysis by Activity Code
- 7.2.8. Word Cloud Analysis: Emerging Focus Areas
- 7.2.9. Popular NIH Departments: Analysis by Number of Grants
- 7.2.10. Prominent Program Officers: Analysis by Number of Grants
- 7.2.11. Popular Recipient Organizations: Analysis by Number of Grants
- 8. PUBLICATION ANALYSIS
- 8.1. Analysis Methodology and Key Parameters
- 8.2. Fc Fusion Therapeutics: Recent Publications
- 8.3. Analysis by Year of Publication
- 8.4. Word Cloud Analysis: Emerging Focus Areas
- 8.5. Analysis by Target Therapeutic Area
- 8.6. Leading Authors: Analysis by Number of Publications
- 8.7. Key Journals: Analysis by Number of Publications
- 9. PATENT ANALYSIS
- 9.1. Analysis Methodology and Key Parameters
- 9.2. Fc Fusion Therapeutics: Patent Analysis
- 9.2.1. Analysis by Publication Year
- 9.2.2. Analysis by Type of Patent
- 9.2.3. Analysis by Geographical Location
- 9.2.4. Analysis by Patent Age
- 9.2.5. Analysis by CPC Symbols
- 9.2.6. Word Cloud Analysis: Emerging Focus Areas
- 9.2.7. Leading Patent Assignees: Analysis by Number of Patents
- 9.2.8. Leading Industry Players: Analysis by Number of Patents
- 9.2.9. Leading Non-Industry Players: Analysis by Number of Patents
- 9.2.10. Fc Fusion Therapeutics: Patent Benchmarking Analysis
- 9.2.10. Fc Fusion Therapeutics: Patent Valuation Analysis
- 10. PARTNERSHIPS AND COLLABORATIONS
- 10.1. Analysis Methodology and Key Parameters
- 10.2. Partnership Models
- 10.3. Fc Fusion Therapeutics: List of Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Type of Partnership and Type of Fusion molecule
- 10.3.4. Analysis by Year of Partnership and Type of Partner
- 10.3.5. Analysis by Type of Partnership and Type of Partner
- 10.3.6. Most Active Players: Analysis by Number of Partnerships
- 10.3.7. Regional Analysis
- 10.3.7.1. Intercontinental and Intracontinental Agreements
- 11. MARKET SIZING AND OPPORTUNITY ANALYSIS
- 11.1. Forecast Methodology and Key Assumptions
- 11.2. Global Fc Fusion Therapeutics Market, 2021-2031
- 11.3. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Target Indication
- 11.4. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Type of Fusion Molecule
- 11.5. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Type of Therapy
- 11.6. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Route of Administration
- 11.7. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Geography
- 11.8. Fc Fusion Therapeutics: Individual Product Sales Forecasts
- 11.8.1. ABP 938 (Amgen)
- 11.8.2. Alprolix® (Sanofi)
- 11.8.3. AnBaiNuo® (Hisun Pharmaceuticals)
- 11.8.4. Arcalyst® (Kiniska Pharmaceuticals)
- 11.8.5. BIVV001 (Sanofi)
- 11.8.6. CD24Fc (Merck)
- 11.8.7. Eloctate® (Biogen)
- 11.8.8. Eylea™ (Regeneron Pharmaceuticals)
- 11.8.9. FRSW107 (Zhengzhou Gensciences)
- 11.8.10. KN035 (Alphamab Oncology)
- 11.8.11. KN046 (Alphamab Oncology)
- 11.8.12. Lumitin® (Chengdu Kanghong Biotech)
- 11.8.13. Reblozyl® (Bristol-Myers Squibb)
- 11.8.14. RyzneutaTM (Evive Biotech)
- 11.8.15. Strensiq® (AstraZeneca)
- 11.8.16. Telitacicept (RemeGen)
- 12. CASE STUDY: FC PROTEIN ENGINEERED AND GLYCOENGINEERED ANTIBODIES
- 12.1. Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline
- 12.1.1. Analysis by Phase of Development
- 12.1.2. Analysis by Target Disease Indication
- 12.1.3. Analysis by Therapeutic Area
- 12.1.4. Analysis by Type of Fc Engineering
- 12.1.5. Analysis by Impact of Fc Engineering
- 12.1.6. Analysis by Route of Administration
- 12.1.7. Analysis by Type of Therapy
- 12.2. Fc Protein Engineered and Glycoengineered Antibodies: List of Developers
- 12.2.1 Analysis by Year of Establishment
- 12.2.2 Analysis by Company Size
- 12.2.3 Analysis by Location of Headquarters
- 13. CONCLUSION
- 14. APPENDIX 1: TABULATED DATA
- 15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 2.1 Executive Summary: Overall Market Landscape
- Figure 2.2 Executive Summary: Clinical Trial Analysis
- Figure 2.3 Executive Summary: Academic Grant Analysis
- Figure 2.4 Executive Summary: Publication Analysis
- Figure 2.5 Executive Summary: Patent Analysis
- Figure 2.6 Executive Summary: Partnerships and Collaborations
- Figure 2.7 Executive Summary: Market Forecast
- Figure 3.1 Components of Fc Fusion Therapeutics
- Figure 3.2 Mechanism of Action
- Figure 4.1 Fc Fusion Therapeutics: Distribution by Phase of Development
- Figure 4.2 Fc Fusion Therapeutics: Distribution by Type of Fusion Molecule
- Figure 4.3 Fc Fusion Therapeutics: Distribution by Target Gene
- Figure 4.4 Fc Fusion Therapeutics: Distribution by Therapeutic Area(s)
- Figure 4.5 Fc Fusion Therapeutics: Distribution by Target Disease Indication(s)
- Figure 4.6 Fc Fusion Therapeutics: Distribution by Type of Therapy
- Figure 4.7 Fc Fusion Therapeutics: Distribution by Route of Administration
- Figure 4.8 Fc Fusion Therapeutics: Distribution by Dosing Frequency
- Figure 4.9 Fc Fusion Therapeutics Developers: Distribution by Year of Establishment
- Figure 4.10 Fc Fusion Therapeutics Developers: Distribution by Company Size
- Figure 4.11 Fc Fusion Therapeutics Developers: Distribution by Location of Headquarters
- Figure 4.12 Leading Developers: Distribution by Number of Fc Fusion Therapeutics
- Figure 4.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
- Figure 5.1 Amgen: Annual Revenues, 2016-H1 2021 (USD Billion)
- Figure 5.2 Acceleron Pharmaceuticals: Annual Revenues, 2016-H1 2021 (USD Billion)
- Figure 5.3 Bristol Myers Squibb: Annual Revenues, 2016-H1 2021 (USD Billion)
- Figure 5.4 Sanofi: Annual Revenues, 2016-H1 2021 (USD Billion)
- Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year
- Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
- Figure 6.3 Clinical Trial Analysis: Distribution by Study Design
- Figure 6.4 Clinical Trial Analysis: Distribution by Type of Masking
- Figure 6.5 Clinical Trial Analysis: Distribution by Type of Intervention Model
- Figure 6.6 World Cloud Analysis: Emerging Focus Areas
- Figure 6.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
- Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor
- Figure 6.9 Leading Industry Players: Distribution by Number of Trials Registered
- Figure 6.10 Leading Non-Industry Players: Distribution by Number of Trials Registered
- Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
- Figure 6.12 Popular Interventions: Distribution by Number of Registered Trials
- Figure 6.13 Popular Indications: Distribution by Number of Registered Trials
- Figure 6.14 Popular Interventions: Distribution by Number of Registered Trials
- Figure 6.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
- Figure 6.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
- Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2010-2021
- Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2010-2021
- Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
- Figure 7.4 Grant Analysis: Distribution by Support Period
- Figure 7.5 Grant Analysis: Distribution by Type of Grant Application
- Figure 7.6 Grant Analysis: Distribution by Purpose of Grant Award
- Figure 7.7 Grant Analysis: Distribution by Activity Code
- Figure 7.8 Word Cloud Analysis: Emerging Focus Areas
- Figure 7.9 Popular NIH Departments: Distribution by Number of Grants
- Figure 7.10 Prominent Program Officers: Distribution by Number of Grants
- Figure 7.11 Popular Recipient Organizations: Distribution by Number of Grants
- Figure 8.1 Publication Analysis: Cumulative Year-wise Trend, 2010-2021
- Figure 8.2 Word Cloud Analysis: Emerging Focus Areas
- Figure 8.3 Publication Analysis: Distribution by Target Therapeutic Area
- Figure 8.4 Leading Authors: Distribution by Number of Publications
- Figure 8.5 Key Journals: Distribution by Number of Publications
- Figure 9.1 Patent Analysis: Distribution by Publication Year
- Figure 9.2 Patent Analysis: Distribution by Type of Patent
- Figure 9.3 Patent Analysis: Distribution by Geographical Location
- Figure 9.4 Patent Analysis: Distribution by Patent Age
- Figure 9.5 Patent Analysis: Distribution by CPC Symbols
- Figure 9.6 Word Cloud Analysis: Emerging Focus Areas
- Figure 9.7 Leading Patent Assignees: Distribution by Number of Patents
- Figure 9.8 Leading Industry Players: Distribution by Number of Patents
- Figure 9.9 Leading Non-Industry Players: Distribution by Number of Patents
- Figure 9.10 Patent Analysis: Distribution by Patent Benchmarking
- Figure 9.11 Patent Analysis: Distribution by Patent Valuation
- Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
- Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 10.3 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Fusion Molecule
- Figure 10.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
- Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
- Figure 10.6 Most Active Players: Distribution by Number of Partnerships
- Figure 10.7 Partnerships and Collaborations: Regional Distribution
- Figure 10.7.1 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
- Figure 11.1 Global Fc Fusion Therapeutics Market, 2021-2030 (USD Million)
- Figure 11.2 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Target Indication (USD Million)
- Figure 11.3 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Type of Fusion Molecule (USD Million)
- Figure 11.4 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Type of Therapy (USD Million)
- Figure 11.5 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Route of Administration (USD Million
- Figure 11.6 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Geography (USD Million)
- Figure 11.7 ABP 938: Sales Forecast, 2024-2030 (USD Million)
- Figure 11.8 Alprolix®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.9 AnBaiNuo®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.10 Arcalyst®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.11 BIVV001: Sales Forecast, 2025-2030 (USD Million)
- Figure 11.12 CD24Fc: Sales Forecast, 2022-2030 (USD Million)
- Figure 11.13 Eloctate®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.14 Eylea™: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.15 FRSW107: Sales Forecast, 2024-2030 (USD Million)
- Figure 11.16 KN035: Sales Forecast, 2024-2030 (USD Million)
- Figure 11.17 KN046: Sales Forecast, 2025-2030 (USD Million)
- Figure 11.18 Lumitin®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.19 Reblozyl®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.20 RyzneutaTM: Sales Forecast, 2022-2030 (USD Million)
- Figure 11.21 Strensiq®: Sales Forecast, 2021-2030 (USD Million)
- Figure 11.21 Telitacicept: Sales Forecast, 2024-2030 (USD Million)
- Figure 12.1 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Phase of Development
- Figure 12.2 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Target Disease Indication
- Figure 12.3 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Therapeutic Area
- Figure 12.4 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Fc Engineering
- Figure 12.5 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Impact of Fc Engineering
- Figure 12.6 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Route of Administration
- Figure 12.7 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Therapy
- Figure 12.8 Fc Protein Engineered and Glycoengineered Antibodies Developers: Analysis by Year of Establishment
- Figure 12.9 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Company Size
- Figure 12.10 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Location of Headquarters
- Figure 13.1 Concluding Remarks: Overall market Landscape
- Figure 13.2 Concluding Remarks: Clinical Trial Analysis
- Figure 13.3 Concluding Remarks: Academic Grants Analysis
- Figure 13.4 Concluding Remarks: Publication Analysis
- Figure 13.5 Concluding Remarks: Patent Analysis
- Figure 13.6 Concluding Remarks: Partnerships and Collaborations
- Figure 13.7 Concluding Remarks: Market Forecast
- LIST OF TABLES
- Table 4.1 Fc Fusion Therapeutics: Drug Pipeline
- Table 4.2 Fc Fusion Therapeutics: List of Drug Developers
- Table 5.1 Fc Fusion Therapeutics: List of Companies Profiled
- Table 5.2 Drug Profile: KN015
- Table 5.3 Drug Profile: KN046
- Table 5.4 Drug Profile: KN035
- Table 5.5 Drug Profile: KN058
- Table 5.6 Drug Profile: KN055
- Table 5.7 Drug Profile: KN019
- Table 5.8 Alphamab Oncology: Recent Developments and Future Outlook
- Table 5.9 Drug Profile: AMG 386
- Table 5.10 Drug Profile: AMG 592
- Table 5.11 Drug Profile: ABP 938
- Table 5.12 Drug Profile: Enbrel®
- Table 5.13 Drug Profile: Nplate®
- Table 5.14 Amgen: Recent Developments and Future Outlook
- Table 5.15 Drug Profile: ACE-1334
- Table 5.16 Drug Profile: ACE-011
- Table 5.17 Acceleron Pharmaceuticals: Recent Developments and Future Outlook
- Table 5.18 Drug Profile: AVID200
- Table 5.19 Drug Profile: Orencia®
- Table 5.20 Drug Profile: Nulojix®
- Table 5.21 Drug Profile: REBLOZYL®
- Table 5.22 Bristol-Myers Squibb: Recent Developments and Future Outlook
- Table 5.23 Drug Profile: Alprolix®
- Table 5.24 Drug Profile: BIVV001
- Table 5.25 Drug Profile: Zaltrap®
- Table 5.26 Sanofi: Recent Developments and Future Outlook
- Table 6.1 Fc Fusion Therapeutics: List of Clinical Trials
- Table 10.1 Fc Fusion Therapeutics: List of Partnerships and Collaborations
- Table 12.1 Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline
- Table 12.2 Fc Protein Engineered and Glycoengineered Antibodies: List of Drug Developers
- Table 14.1 Fc Fusion Therapeutics: Distribution by Phase of Development
- Table 14.2 Fc Fusion Therapeutics: Distribution by Type of Fusion Molecule
- Table 14.3 Fc Fusion Therapeutics: Distribution by Target Gene
- Table 14.4 Fc Fusion Therapeutics: Distribution by Therapeutic Area(s)
- Table 14.5 Fc Fusion Therapeutics: Distribution by Target Disease Indication(s)
- Table 14.6 Fc Fusion Therapeutics: Distribution by Type of Therapy
- Table 14.7 Fc Fusion Therapeutics: Distribution by Route of Administration
- Table 14.8 Fc Fusion Therapeutics: Distribution by Dosing Frequency
- Table 14.9 Fc Fusion Therapeutics: Distribution by Year of Establishment
- Table 14.10 Fc Fusion Therapeutics: Distribution by Company Size
- Table 14.11 Fc Fusion Therapeutics: Distribution by Location of Headquarters
- Table 14.12 Fc Fusion Therapeutics: Distribution by Leading Developers
- Table 14.13 Amgen: Annual Revenues, 2016-H1 2021 (USD Billion)
- Table 14.14 Acceleron Pharmaceuticals: Annual Revenues, 2016-H1 2021 (USD Billion)
- Table 14.15 Bristol Myers Squibb: Annual Revenues, 2016-H1 2021 (USD Billion)
- Table 14.16 Sanofi: Annual Revenues, 2016-H1 2021 (USD Billion)
- Table 14.17 Clinical Trial Analysis: Distribution by Trial Registration Year
- Table 14.18 Clinical Trial Analysis: Distribution by Trial Phase
- Table 14.19 Clinical Trial Analysis: Distribution by Study Design
- Table 14.20 Clinical Trial Analysis: Distribution by Type of Masking
- Table 14.21 Clinical Trial Analysis: Distribution by Type of Intervention Model
- Table 14.22 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
- Table 14.23 Clinical Trial Analysis: Distribution by Type of Sponsor
- Table 14.24 Leading Industry Players: Distribution by Number of Trials Registered
- Table 14.25 Leading Non-Industry Players: Distribution by Number of Trials Registered
- Table 14.26 Popular Indications: Analysis by Number of Registered Trials
- Table 14.27 Popular Interventions: Analysis by Number of Registered Trials
- Table 14.28 Popular Indications: Distribution by Number of Registered Trials
- Table 14.29 Popular Interventions: Distribution by Number of Registered Trials
- Table 14.30 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
- Table 14.31 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
- Table 14.32 Grant Analysis: Cumulative Trend by Year of Grant Award, 2010-2021
- Table 14.33 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2010-2021
- Table 14.34 Grant Analysis: Distribution by Administering Institute Center
- Table 14.35 Grant Analysis: Distribution by Support Period
- Table 14.36 Grant Analysis: Distribution by Type of Grant Application
- Table 14.37 Grant Analysis: Distribution by Purpose of Grant Award
- Table 14.38 Grant Analysis: Distribution by Activity Code
- Table 14.39 Popular NIH Departments: Distribution by Number of Grants
- Table 14.40 Prominent Program Officers: Distribution by Number of Grants
- Table 14.41 Popular Recipient Organizations: Distribution by Number of Grants
- Table 14.42 Publication Analysis: Cumulative Year-wise Trend, 2010-2021
- Table 14.43 Publication Analysis: Distribution by Target Therapeutic Area
- Table 14.44 Leading Authors: Distribution by Number of Publications
- Table 14.45 Key Journals: Distribution by Number of Publications
- Table 14.46 Patent Analysis: Distribution by Publication Year
- Table 14.47 Patent Analysis: Distribution by Type of Patent
- Table 14.48 Patent Analysis: Distribution by Geographical Location
- Table 14.49 Patent Analysis: Distribution by Patent Age
- Table 14.50 Patent Analysis: Distribution by CPC Symbols
- Table 14.51 Leading Patent Assignees: Distribution by Number of Patents
- Table 14.52 Leading Industry Players: Distribution by Number of Patents
- Table 14.53 Patent Analysis: Distribution by Patent Benchmarking
- Table 14.54 Patent Analysis: Distribution by Patent Valuation
- Table 14.55 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
- Table 14.56 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 14.57 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Fusion Molecule
- Table 14.58 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
- Table 14.59 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
- Table 14.60 Most Active Players: Distribution by Number of Partnerships
- Table 14.61 Partnerships and Collaborations: Regional Distribution
- Table 14.62 Global Fc Fusion Therapeutics Market, 2021-2030 (USD Million)
- Table 14.63 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Target Indication (USD Million)
- Table 14.64 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Type of Therapy (USD Million)
- Table 14.65 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Route of Administration (USD Million
- Table 14.66 Global Fc Fusion Therapeutics Market, 2021-2030: Distribution by Geography (USD Million)
- Table 14.67 ABP 938: Sales Forecast, 2024-2030 (USD Million)
- Table 14.68 Alprolix®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.69 AnBaiNuo®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.70 Arcalyst®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.71 BIVV001: Sales Forecast, 2025-2030 (USD Million)
- Table 14.72 CD24Fc: Sales Forecast, 2022-2030 (USD Million)
- Table 14.73 Eloctate®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.74 Eylea™: Sales Forecast, 2021-2030 (USD Million)
- Table 14.75 FRSW107: Sales Forecast, 2024-2030 (USD Million)
- Table 14.76 KN035: Sales Forecast, 2024-2030 (USD Million)
- Table 14.77 KN046: Sales Forecast, 2025-2030 (USD Million)
- Table 14.78 Lumitin®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.79 Reblozyl®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.80 RyzneutaTM: Sales Forecast, 2022-2030 (USD Million)
- Table 14.81 Strensiq®: Sales Forecast, 2021-2030 (USD Million)
- Table 14.82 Telitacicept: Sales Forecast, 2024-2030 (USD Million)
- Table 14.83 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Phase of Development
- Table 14.84 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Target Disease Indication
- Table 14.85 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Therapeutic Area
- Table 14.86 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Fc Engineering
- Table 14.87 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Impact of Fc Engineering
- Table 14.88 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Route of Administration
- Table 14.89 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Therapy
- Table 14.90 Fc Protein Engineered and Glycoengineered Antibodies Developers: Analysis by Year of Establishment
- Table 14.91 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Company Size
- Table 14.92 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Location of Headquarters
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
